Melanoma/Skin Cancer News

Patients treated with cemiplimab for advanced cutaneous squamous cell carcinoma had improvements to quality of life, pain and other symptoms, according to a presentation at South Beach Symposium Medical Dermatology Summit.

Klisyri, an FDA-approved Src kinase signaling inhibitor, was superior to placebo for the treatment of actinic keratoses, according to findings from two double-blind randomized trials published in The New England Journal of Medicine.

The FDA granted regular approval to cemiplimab-rwlc for patients with locally advanced basal cell carcinoma who were previously treated with or ineligible for treatment with a hedgehog pathway inhibitor.

Patients with basal cell carcinoma who discontinued hedgehog inhibitors had differing odds for reinitiation that varied by grace period, according to a presentation at Maui Derm for Dermatologists.

The FDA granted fast track designation to TH1902 for treatment of certain patients with sortilin-expressing cancers, according to the agent’s manufacturer.

Patients with advanced cutaneous squamous cell carcinoma had an “increasing, clinically meaningful” duration of response with cemiplimab, according to results from a phase 2 study presented at Maui Derm for Dermatologists.

The FDA granted fast track designation to toripalimab for the first-line treatment of patients with mucosal melanoma, according to a manufacturer-issued press release.

Anal carcinoma risk was significantly higher among individuals with HIV and a history of anal or genital warts than among those with no history of these warts, according to a study.

The FDA granted fast track designation to cavrotolimod for two skin cancer indications, according to the agent’s manufacturer.

Adoptive cell therapies have proved highly effective for patients with certain advanced cancers, particularly melanoma and hematologic malignancies.